1. "Hematologic Malignancies, Division of"
Formats
  1. Meeting Abstract (6211)
  2. Journal Article (5696)
  3. Review (405)
  4. Book Section (186)
  5. Editorial (186)
  6. Research Letter (169)
  7. Guidelines (86)
  8. Conference Paper (65)
  9. Correspondence (58)
  10. Miscellaneous (17)
  11. Book Whole (9)
Groups
  1. Hematologic Malignancies, Division of (13088)
  2. Department of Medicine (13004)
  3. Center for Hematologic Malignancies (10395)
  4. GSK Faculty (4422)
  5. Adult Leukemia (3583)
  6. Bone Marrow Transplant (2776)

More Groups

People
  1. Sergio Giralt (1050)
  2. Miguel-Angel Perales (913)
  3. Ross Levine (775)
  4. Andrew Zelenetz (767)
  5. Martin Tallman (649)
  6. Steven Horwitz (645)

More People

Years
  1. 2025 (204)
  2. 2024 (670)
  3. 2023 (1038)
  4. 2022 (964)
  5. 2021 (875)
  6. 2020 (936)

More Years

Publications
  1. Blood (3371)
  2. Journal of Clinical Oncology (1214)
  3. Biology of Blood and Marrow Transplantation (596)
  4. Clinical Lymphoma, Myeloma and Leukemia (328)
  5. Haematologica (289)
  6. Bone Marrow Transplantation (238)

More Publications

Publishers
  1. American Society of Hematology (3638)
  2. Elsevier Inc. (1609)
  3. American Society of Clinical Oncology (1266)
  4. Nature Publishing Group (994)
  5. American Association for Cancer Research (637)
  6. Wiley Blackwell (431)

More Publishers

Results (13088)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Risk of MGUS, a multiple myeloma precursor, in relation to food and beverage intake in the National Health and Nutrition Examination Survey (NHANES)
    Meeting Abstract

    Joseph, J.; Tang, L.; Hillengass, J.; Landgren, O.; Usmani, S. Z.; Lesokhin, A. M.; Moysich, K. B.; Shah, U. A.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Belantamab mafodotin (belamaf) for relapsed/refractory multiple myeloma (RRMM): A real-world observational study update
    Meeting Abstract

    Hultcrantz, M.; Kleinman, D.; Vij, R.; Escalante, F.; Delforge, M.; Kotowsky, N.; Bitetti, J.; Boytsov, N.; Camadoo-O'Byrne, L.; Powers Happ, L.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Five-year subgroup analysis of tafasitamab + lenalidomide from the phase II L-MIND study in patients with relapsed or refractory diffuse large B-cell lymphoma
    Meeting Abstract

    Duell, J.; Abrisqueta, P.; Dreyling, M. H.; Gaidano, G.; González Barca, E.; Jurczak, W.; Maddocks, K. J.; Menne, T.; Tournilhac, O.; Bakuli, A.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Molecular features and outcomes for patients receiving elranatamab for relapsed or refractory multiple myeloma in MagnetisMM-1
    Meeting Abstract

    Tomasson, M. H.; Bahlis, N. J.; Costello, C.; Raje, N. S.; Levy, M. Y.; Dholaria, B. R.; Solh, M. M.; Damore, M. A.; Jiang, S.; Xie, T.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Predictors of resistance to trastuzumab deruxtecan (T-DXd) in esophagogastric adenocarcinoma (EGC)
    Meeting Abstract

    Tsai, C.; Chou, J. F.; Biachi de Castria, T.; Tang, L. H.; Ilson, D. H.; Ku, G. Y.; Schultz, N.; Capanu, M.; Janjigian, Y. Y.; Maron, S. B.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • The SPEARHEAD-1 trial of afamitresgene autoleucel (afami-cel [formerly ADP-A2M4]): Pooled analysis of cytokine release syndrome across cohorts in patients with advanced synovial sarcoma
    Meeting Abstract

    D'Angelo, S. P.; Ganjoo, K. N.; Blay, J. Y.; Valverde, C.; Araujo, D. M.; Abdul Razak, A. R.; Le Cesne, A.; Schuetze, S.; Wagner, M. J.; Attia, S.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Patient- versus clinician-reported symptoms in the POLARIX study
    Meeting Abstract

    Thompson, C. A.; Mehta-Shah, N.; Flowers, C.; Salles, G. A.; Tilly, H.; Chua, N. S.; Casasnovas, R. O.; Miall, F.; Kim, T. M.; Tsai, C. H.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • The SPEARHEAD-1 trial of afamitresgene autoleucel (afami-cel [formerly ADP-A2M4]): Analysis of overall survival in advanced synovial sarcoma
    Meeting Abstract

    Van Tine, B. A.; Ganjoo, K. N.; Blay, J. Y.; Valverde, C.; Araujo, D. M.; Abdul Razak, A. R.; Le Cesne, A.; Schuetze, S.; Wagner, M. J.; Attia, S.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A phase II study of talimogene laherparepvec (T-VEC) and pembrolizumab in patients with advanced sarcoma: Results of expansion cohorts
    Meeting Abstract

    Kelly, C. M.; Avutu, V.; Chi, P.; Dickson, M. A.; Gounder, M. M.; Keohan, M. L.; Movva, S.; Rosenbaum, E.; Cordover, E.; Ariyan, C. E.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A pilot study of lenvatinib plus pembrolizumab in patients with advanced sarcoma
    Meeting Abstract

    Movva, S.; Avutu, V.; Chi, P.; Dickson, M. A.; Gounder, M. M.; Kelly, Ciara M.; Keohan, M. L.; Meyers, P. A.; Cohen, S. M.; Hensley, M. L.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save